journal article·2022-06

An aromatase inhibitor in combination with Zinc(II) phthalocyanine for targeted therapy of post-menopausal breast cancer

Gankun Yuan, Qilu Wang, Kunshan Huang, Jinping Xue, Juanjuan Chen

Dyes and Pigments· Volume 202
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Photodynamic Therapy Research Studies · Nanoplatforms for cancer theranostics · Porphyrin and Phthalocyanine Chemistry

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (60)

Show source-provided references
1. Estrogen receptor-positive (ER+) breast cancer treatment: are multi-target compounds the next promising approach10.1016/j.bcp.2020.113989 ↗
2. Understanding breast cancer-The long and winding road10.1016/j.bbacli.2017.01.001 ↗
3. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
4. An “Omics” approach to determine the mechanisms of acquired aromatase inhibitor resistance10.1089/omi.2010.0097 ↗
5. Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development10.1542/peds.2007-2081 ↗
6. Aromatase inhibitors: role in postmenopausal breast cancer10.1002/ardp.202000081 ↗
7. Harnessing a different dependency: how to identify and target androgen receptor-positive versus quadruple-negative breast cancer10.1007/s12672-017-0314-5 ↗
8. Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant10.1136/esmoopen-2016-000062 ↗
9. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer10.1016/S0093-7754(03)00302-6 ↗
10. Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and –resistant breast cancer cells10.1016/j.jsbmb.2015.07.018 ↗
11. Shell-crosslinked zein nanocapsules for oral codelivery of exemestane and resveratrol in breast cancer therapy10.2217/nnm-2017-0247 ↗
12. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study
13. Exemestane encapsulated polymer-lipid hybrid nanoparticles for improved efficacy against breast cancer: optimization, in vitro characterization and cell culture studies10.1088/1361-6528/ac1098 ↗
14. Nanostructured lipid carriers for oral bioavailability enhancement of exemestane: formulation design, in vitro, ex vivo, and in vivo studies10.1016/j.xphs.2019.06.003 ↗
15. Scott · Exemestane. Drugs · 1999 · 58 · 67510.2165/00003495-199958040-00007 ↗
16. Exemestane loaded alginate nanoparticles for cancer treatment: formulation and in vitro evaluation10.1016/j.ijbiomac.2017.07.064 ↗
17. Twelve-month estrogen levels in premenopausal women with hormone receptor–positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy10.1200/JCO.2015.61.2259 ↗
18. A new genetic risk score to predict the outcome of locally advanced or metastatic breast cancer patients treated with first-line exemestane: results from a prospective study10.1016/j.clbc.2018.11.009 ↗
19. Insights on the interaction mechanism of exemestane to three digestive enzymes by multi-spectroscopy and molecular docking10.1016/j.ijbiomac.2021.07.079 ↗
20. Aromatase inhibitor associated arthralgia: the importance of oncology provider-patient communication about side effects and potential management through physical activity
21. Clinical utility of exemestane in the treatment of breast cancer10.2147/IJWH.S69475 ↗
22. Aromatase inhibitors in the breast cancer clinic: focus on exemestane10.1530/ERC-13-0269 ↗
23. Molecular targeted study in tumors: from western medicine to active ingredients of traditional Chinese medicine10.1016/j.biopha.2019.109624 ↗
24. Targeting tumour-supportive cellular machineries in anticancer drug development10.1038/nrd4201 ↗
25. Molecular targeted therapy of cancer: the progress and future prospect10.1016/j.flm.2017.06.001 ↗
26. Molecular targeted therapy: treating cancer with specificity10.1016/j.ejphar.2018.07.034 ↗
27. Photodynamic therapy for cancer10.1038/nrc1071 ↗
28. The present and future role of photodynamic therapy in cancer treatment10.1016/S1470-2045(04)01529-3 ↗
29. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization10.1021/cr900300p ↗
30. A dual-targeted organic photothermal agent for enhanced photothermal therapy10.1002/anie.201811273 ↗
31. Targeted delivery of chlorin e6 via redox sensitive diselenide-containing micelles for improved photodynamic therapy in cluster of differentiation 44-overexpressing breast cancer10.3389/fphar.2019.00369 ↗
32. Tumor-targeting photodynamic therapy based on folate-modified polydopamine nanoparticles10.2147/IJN.S216194 ↗
33. Photodynamic therapy for treatment of solid tumors-potential and technical challenges10.1177/153303460800700405 ↗
34. Photodynamic therapeutics: basic principles and clinical applications10.1016/S1359-6446(99)01412-9 ↗
35. A novel strategy for targeting photodynamic therapy. Molecular combo of photodynamic agent zinc(II) phthalocyanine and small molecule target-based anticancer drug erlotinib10.1039/c3cc45487h ↗
36. Silicon phthalocyanines axially disubstituted with erlotinib toward small-molecular-target-based photodynamic therapy10.1002/cmdc.201700384 ↗
37. Dennis. A multifunctional molecular therapeutic agent for targeted and controlled dual chemo- and photodynamic therapy10.1021/acs.jmedchem.0c00893 ↗
38. Photodynamic oncotherapy mediated by gonadotropin-releasing hormone receptors10.1021/acs.jmedchem.7b01216 ↗
39. Water-soluble chlorin/arylaminoquinazoline conjugate for photodynamic and targeted therapy10.1021/acs.jmedchem.9b01294 ↗
40. Hepatocyte-targeting single galactose-appended naphthalimide: a tool for intracellular thiol imaging in vivo10.1021/ja210065g ↗
41. Phthalocyanine–peptide conjugates: receptor-targeting bifunctional agents for imaging and photodynamic therapy10.1021/jm301311c ↗
42. A novel zinc phthalocyanine-indometacin photosensitizer with “Three-in-one” cyclooxygenase-2-driven dual targeting and aggregation inhibition for high-efficient anticancer therapy10.1016/j.dyepig.2021.109997 ↗
43. In vivo covalent cross-linking of photon-converted rare-earth nanostructures for tumour localization and theranostics10.1038/ncomms10432 ↗
44. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy10.7150/thno.3463 ↗
45. A novel tumor and mitochondria dual-targeted photosensitizer showing ultra-efficient photodynamic anticancer activities10.1039/C8CC09456J ↗
46. An epidermal growth factor receptor-targeted and endoplasmic reticulum-localized organic photosensitizer toward photodynamic anticancer therapy10.1016/j.ejmech.2019.111625 ↗
47. Recent advances in supramolecular activatable phthalocyanine-based photosensitizers for anti-cancer therapy10.1016/j.ccr.2021.214155 ↗
48. Stimuli responsive phthalocyanine-based fluorescent probes and photosensitizers10.1016/j.ccr.2017.10.006 ↗
49. Nanostructured phthalocyanine assemblies with protein-driven switchable photoactivities for biophotonic imaging and therapy10.1021/jacs.7b05916 ↗
50. Photodynamic cell-kill analysis of breast tumor cells with a tamoxifen-pyropheophorbide conjugate10.1002/jcb.20932 ↗
51. A molecular combo of zinc(II) phthalocyanine and tamoxifen derivative for dual targeting photodynamic therapy and hormone therapy10.1021/acs.jmedchem.7b00682 ↗
52. Novel targeted photosensitizer as an immunomodulator for highly efficient therapy of T-Cell acute lymphoblastic leukemia10.1021/acs.jmedchem.0c01072 ↗
53. J-aggregates: from serendipitous discovery to supramolecular engineering of functional dye materials10.1002/anie.201002307 ↗
54. Exchange narrowing of the J band of molecular dye aggregates10.1063/1.2823730 ↗
55. Theory of the J-band: fom the frenkel exciton to charge transfer10.1016/j.phpro.2009.07.014 ↗
56. Synthesis, properties, and photodynamic inactivation of Escherichia coli using a cationic and a noncharged Zn(II) pyridyloxyphthalocyanine derivatives10.1016/j.bmc.2005.01.063 ↗
57. Photosensitizer delivery and photosensitization for enhanced photodynamic therapy with ultralow irradiance10.1002/adfm.201402255 ↗
58. Synthesis and in vitro biological evaluation of lipophilic cation conjugated photosensitizers for targeting mitochondria10.1016/j.bmc.2012.11.032 ↗
59. A near-infrared triggered nanophotosensitizer inducing domino effect on mitochondrial reactive oxygen species burst for cancer therapy10.1021/acsnano.5b04501 ↗
60. Acidity-triggered tumor-targeted chimeric peptide for enhanced intra-nuclear photodynamic therapy10.1002/adfm.201600170 ↗